Clinical Approach to Ambiguous Genitalia

Disorders of Sex Development – Pediatric Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of ambiguous genitalia

Ambiguous genitalia, now classified under Disorders of Sex Development (DSD), represents one of the most challenging presentations in neonatal medicine. Occurring in approximately 1 in 4,500 live births, this condition requires urgent multidisciplinary evaluation due to potential life-threatening associations such as salt-wasting congenital adrenal hyperplasia. The birth of an infant with atypical genitalia constitutes both a medical and psychosocial emergency, demanding sensitive communication with families while initiating a systematic diagnostic workup.

Definition

Ambiguous genitalia refers to external genitalia that do not have the typical appearance of either male or female anatomy, making sex assignment difficult at birth. The term Disorders of Sex Development (DSD) encompasses congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. This terminology, established by the 2006 Chicago Consensus, replaces older terms such as “intersex,” “hermaphroditism,” and “pseudohermaphroditism.”

Critical Alert: Salt-Wasting Crisis

Congenital adrenal hyperplasia (CAH) accounts for approximately 60-70% of ambiguous genitalia cases in 46,XX infants. Salt-wasting CAH can present with life-threatening adrenal crisis typically between days 7-14 of life. Every infant with ambiguous genitalia must be monitored for signs of adrenal insufficiency including poor feeding, vomiting, lethargy, dehydration, hyponatremia, and hyperkalemia.

Key Epidemiology

Overall incidence: Approximately 1 in 4,500 live births present with genital ambiguity requiring specialist evaluation

Congenital adrenal hyperplasia: 1 in 15,000 live births (most common cause); 21-hydroxylase deficiency accounts for 90-95% of CAH cases

Complete androgen insensitivity syndrome: 1 in 20,000-64,000 XY births

5-alpha reductase deficiency: Rare globally but higher prevalence in certain populations (Dominican Republic, Papua New Guinea)

Mixed gonadal dysgenesis: Second most common cause of ambiguous genitalia in 46,XY individuals

Classification of Disorders of Sex Development

The modern classification system categorizes DSD based on karyotype, providing a systematic framework for diagnosis and management. This approach acknowledges that genital phenotype exists on a spectrum and does not always correlate directly with chromosomal or gonadal sex.

DSD Category	Karyotype	Examples	Key Features
46,XX DSD	46,XX	Congenital adrenal hyperplasia, aromatase deficiency, maternal androgen exposure, ovotesticular DSD	Virilization of female fetus; ovaries typically present; most commonly due to excess androgens
46,XY DSD	46,XY	Androgen insensitivity syndrome, 5-alpha reductase deficiency, disorders of testicular development, disorders of androgen synthesis	Undervirilization of male fetus; testes may be present but dysfunctional; defects in androgen production or action
Sex Chromosome DSD	45,X/46,XY; 46,XX/46,XY; 47,XXY	Mixed gonadal dysgenesis, ovotesticular DSD, Klinefelter syndrome variants	Mosaicism common; variable phenotype; gonadal dysgenesis or asymmetric gonadal development

Clinical Presentation Spectrum

The phenotype of ambiguous genitalia varies widely, from near-typical female or male appearance to completely indeterminate external genitalia. The Prader scale (for 46,XX DSD) and External Masculinization Score (EMS) help standardize description and documentation.

Prader Stage	Description	Clinical Appearance
Stage 0	Normal female	Typical female external genitalia
Stage I	Female with clitoromegaly	Clitoral enlargement only; separate urethral and vaginal openings
Stage II	Clitoromegaly with partial labial fusion	Enlarged clitoris; posterior labial fusion; urogenital sinus present
Stage III	Increased phallic size, single perineal orifice	Phallus-like clitoris; complete labioscrotal fusion; single urogenital opening
Stage IV	Phallic urethra, scrotal-like labia	Penile urethra not reaching glans; chordee common; scrotal appearance
Stage V	Normal male appearance	Typical male external genitalia with penile urethra; may have cryptorchidism

Features Indicating Need for Specialist Evaluation

Not all genital variations require full DSD workup. The following findings should prompt specialist referral and comprehensive evaluation:

Phenotypically Female Infant

Clitoromegaly (clitoral length greater than 9 mm)
Posterior labial fusion
Inguinal hernia containing gonad
Single perineal opening
Non-palpable gonads with above features

Phenotypically Male Infant

Bilateral cryptorchidism
Unilateral cryptorchidism with hypospadias
Severe hypospadias (perineal or scrotal)
Micropenis (stretched length less than 2.5 cm)
Bifid scrotum

Timing Considerations

The urgency of evaluation depends on the potential for underlying life-threatening conditions and the psychosocial impact on the family.

Timeframe	Priority Actions	Rationale
Immediate (Day 1)	Clinical assessment, karyotype, 17-hydroxyprogesterone, electrolytes, family support	Rule out CAH; prevent salt-wasting crisis; support family through uncertainty
Urgent (Days 1-3)	Pelvic ultrasound, additional hormone studies, multidisciplinary team assembly	Identify internal structures; guide differential diagnosis; coordinate care
Early (Week 1-2)	Complete hormonal workup, genetic studies, family meetings	Establish diagnosis; discuss prognosis and management options with family
Ongoing	Sex assignment decision, surgical planning (if indicated), long-term follow-up	Individualized management; psychological support; transition planning

Key Concept: The Multidisciplinary DSD Team

Optimal management of ambiguous genitalia requires a coordinated multidisciplinary approach including: pediatric endocrinologist, pediatric urologist or surgeon, geneticist, neonatologist, psychologist or psychiatrist, social worker, and nursing specialists. Early involvement of this team improves outcomes and family satisfaction. Sex assignment should be deferred until adequate diagnostic information is available and should involve shared decision-making with the family.

Communication with Families

The initial conversation with parents is crucial and sets the tone for the therapeutic relationship. Key principles include:

Use neutral language: Refer to “your baby” rather than gendered pronouns until sex assignment is made
Acknowledge uncertainty: Explain that determining sex requires careful evaluation and may take several days
Provide reassurance: Emphasize that the baby is otherwise healthy (if true) and that expert help is available
Delay birth registration: In most jurisdictions, birth certificate completion can be deferred while evaluation proceeds
Offer psychological support: Early involvement of mental health professionals benefits families

2. Pathophysiology and Mechanisms

Understanding normal sexual differentiation and how it goes awry

Understanding ambiguous genitalia requires a firm grasp of normal sexual differentiation. Human sex development is a complex, sequential process involving genetic determination, gonadal differentiation, and hormonal action on target tissues. Disruption at any step can result in atypical genital development. The timing and nature of the disruption determines the phenotypic outcome.

Normal Sexual Differentiation: A Three-Stage Process

Stage	Timing	Key Events	Critical Factors
1. Chromosomal Sex	Conception	Determined by sperm carrying X or Y chromosome; establishes genetic sex (46,XX or 46,XY)	Sex chromosomes; particularly presence or absence of SRY gene
2. Gonadal Sex	Weeks 6-7	Bipotential gonad differentiates into testis or ovary; requires specific gene activation	SRY gene (testis); absence of SRY allows ovarian development; SOX9, SF1, WT1, DAX1
3. Phenotypic Sex	Weeks 8-14	Internal and external genitalia develop under hormonal influence; masculinization requires active hormone signaling	Testosterone, dihydrotestosterone (DHT), anti-Müllerian hormone (AMH), androgen receptor function

The Bipotential Gonad and Differentiation Pathways

Until approximately 6 weeks of gestation, the gonad is bipotential, capable of becoming either testis or ovary. Both Wolffian (mesonephric) and Müllerian (paramesonephric) duct systems are present. The subsequent pathway depends primarily on the presence of the SRY gene on the Y chromosome.

Male Pathway (46,XY)

Week 6-7: SRY gene activates SOX9, initiating testis differentiation

Week 8: Sertoli cells produce anti-Müllerian hormone (AMH), causing Müllerian duct regression

Week 8-14: Leydig cells produce testosterone, stimulating Wolffian duct development (epididymis, vas deferens, seminal vesicles)

Week 8-14: 5-alpha reductase converts testosterone to DHT, which masculinizes external genitalia

Female Pathway (46,XX)

Week 6-7: Absence of SRY allows ovarian differentiation pathway (WNT4, RSPO1 signaling)

Week 10-11: Without AMH, Müllerian ducts develop into uterus, fallopian tubes, and upper vagina

Week 8-14: Without testosterone, Wolffian ducts regress

Week 8-14: Without DHT, external genitalia remain female (clitoris, labia, lower vagina)

Clinical Pearl: The “Default” Pathway Concept

Female development was historically described as the “default” pathway, but this is an oversimplification. Active gene expression (WNT4, RSPO1, FOXL2) is required for ovarian development and maintenance. Disruption of these pathways can cause ovarian dysfunction or even ovotestis formation in 46,XX individuals. Think of sexual differentiation as two competing active pathways rather than one active (male) and one passive (female).

Key Hormones and Their Roles

Hormone	Source	Function in Male Development	Clinical Relevance
Anti-Müllerian Hormone (AMH)	Sertoli cells	Causes regression of Müllerian ducts (prevents uterus/fallopian tube formation)	Persistent Müllerian duct syndrome occurs with AMH or AMH receptor defects; phenotypically male with uterus
Testosterone	Leydig cells	Stimulates Wolffian duct development; converted to DHT for external masculinization	Deficiency causes undervirilization; excess causes virilization of 46,XX fetus
Dihydrotestosterone (DHT)	Peripheral conversion by 5-alpha reductase	Masculinizes external genitalia (penis, scrotum); prostate development	5-alpha reductase deficiency causes undervirilized external genitalia with normal internal male structures
Human Chorionic Gonadotropin (hCG)	Placenta (early); then fetal pituitary LH	Stimulates fetal Leydig cell testosterone production	Used diagnostically in hCG stimulation test to assess testicular function

External Genital Development: The Critical Window

External genital differentiation occurs primarily between weeks 8-14 of gestation. This represents the critical window for androgen action on genital tissue.

Structure	Precursor	Male Development (with DHT)	Female Development (without DHT)
Genital tubercle	Genital tubercle	Glans penis	Clitoris
Urogenital folds	Urethral folds	Penile urethra (fused)	Labia minora (unfused)
Labioscrotal swellings	Labioscrotal folds	Scrotum (fused)	Labia majora (unfused)
Urogenital sinus	Urogenital sinus	Prostate, prostatic urethra	Lower vagina, urethra

Mechanisms of Ambiguous Genitalia by DSD Category

46,XX DSD: Virilization of Female Fetus

Condition	Mechanism	Source of Androgens	Key Features
21-Hydroxylase Deficiency (CAH)	Enzyme deficiency blocks cortisol synthesis; ACTH rises; adrenal steroid precursors shunted to androgen pathway	Fetal adrenal gland	Most common cause (90-95% of CAH); 75% have salt-wasting form; elevated 17-hydroxyprogesterone diagnostic
11-Beta-Hydroxylase Deficiency	Enzyme deficiency causes cortisol deficiency and accumulation of 11-deoxycortisol and 11-deoxycorticosterone	Fetal adrenal gland	Hypertension common (mineralocorticoid effect of accumulated precursors); second most common CAH form
3-Beta-Hydroxysteroid Dehydrogenase Deficiency	Impaired steroid synthesis in adrenal and gonad; weak androgen (DHEA) accumulation	Fetal adrenal gland	Variable virilization in XX; undervirilization in XY; salt-wasting common
Aromatase Deficiency	Cannot convert androgens to estrogens; fetal androgens not inactivated by placenta	Fetal and placental	Maternal virilization during pregnancy; fetal virilization; progressive signs in affected female
Maternal Androgen Exposure	Exogenous androgens or androgen-secreting tumor cross placenta	Maternal	Timing of exposure determines severity; includes luteoma, medications, CAH in mother

46,XY DSD: Undervirilization of Male Fetus

Category	Condition	Mechanism	Key Features
Disorders of Gonadal Development	Complete Gonadal Dysgenesis (Swyer Syndrome)	Streak gonads fail to produce testosterone or AMH; no masculinization occurs	Female external genitalia; Müllerian structures present; 46,XY karyotype; gonadal malignancy risk
Disorders of Gonadal Development	Partial Gonadal Dysgenesis	Dysgenetic testes produce some but insufficient testosterone/AMH	Variable ambiguity; asymmetric gonads common; high malignancy risk
Disorders of Androgen Synthesis	17-Alpha-Hydroxylase Deficiency	Cannot synthesize cortisol or sex steroids; mineralocorticoid excess	Undervirilized XY; hypertension; hypokalemia; absent puberty
	17-Beta-Hydroxysteroid Dehydrogenase Deficiency	Cannot convert androstenedione to testosterone	Female phenotype at birth; virilization at puberty; often raised as female
	Leydig Cell Hypoplasia	LH receptor defect; Leydig cells cannot respond to LH/hCG stimulation	Variable phenotype; low testosterone that does not rise with hCG stimulation
Disorders of Androgen Action	Complete Androgen Insensitivity Syndrome (CAIS)	Non-functional androgen receptor; tissues cannot respond to testosterone or DHT	Female external genitalia; testes present (often inguinal); no uterus; primary amenorrhea presentation
Disorders of Androgen Action	Partial Androgen Insensitivity Syndrome (PAIS)	Partially functional androgen receptor; variable tissue response	Variable ambiguity; wide phenotypic spectrum; may present as infertile male or virilized female
5-Alpha Reductase Deficiency	5-Alpha Reductase Type 2 Deficiency	Cannot convert testosterone to DHT; internal masculinization normal but external genitalia undervirilized	Female or ambiguous external genitalia at birth; marked virilization at puberty; often gender identity change

Sex Chromosome DSD

Condition	Karyotype	Mechanism	Key Features
Mixed Gonadal Dysgenesis	45,X/46,XY mosaicism	Asymmetric gonadal development; one streak gonad and one dysgenetic testis typically	Variable phenotype; asymmetric internal structures; high gonadal malignancy risk; second most common DSD in 46,XY
Ovotesticular DSD	46,XX most common; can be 46,XY or mosaic	Both ovarian and testicular tissue present (may be as ovotestis or separate gonads)	Variable phenotype; fertility possible in some cases; previously called “true hermaphroditism”
Turner Syndrome Variants	45,X/46,XY or 45,X/46,XX	Variable gonadal development depending on cell line proportions	May have ambiguity; gonadal evaluation essential; malignancy risk if Y material present

Clinical Pearl: Puberty Reveals the Diagnosis

Some conditions present with ambiguous or female-appearing genitalia at birth but undergo significant virilization at puberty. This occurs in 5-alpha reductase deficiency and 17-beta-hydroxysteroid dehydrogenase deficiency because the pubertal testosterone surge can partially compensate for the enzyme deficiency. These conditions are sometimes called “penis-at-twelve” syndromes in populations where they are endemic. The dramatic pubertal changes can lead to gender identity shifts, highlighting the importance of early diagnosis when possible.

Adrenal Steroid Synthesis Pathway

Understanding the steroidogenesis pathway is essential for interpreting hormonal results in CAH and related conditions. Enzyme deficiencies cause accumulation of precursors proximal to the block and deficiency of products distal to it.

Simplified Pathway from Cholesterol:

Cholesterol → (StAR protein) → Pregnenolone → (3β-HSD) → Progesterone → (21-OH) → 11-Deoxycorticosterone → (11β-OH) → Corticosterone → Aldosterone

Pregnenolone → (17α-OH) → 17-OH Pregnenolone → (3β-HSD) → 17-OH Progesterone → (21-OH) → 11-Deoxycortisol → (11β-OH) → Cortisol

17-OH Pregnenolone → (17,20 lyase) → DHEA → (3β-HSD) → Androstenedione → (17β-HSD) → Testosterone → (5α-reductase) → DHT

Key enzymes: StAR = steroidogenic acute regulatory protein; 3β-HSD = 3-beta-hydroxysteroid dehydrogenase; 21-OH = 21-hydroxylase; 11β-OH = 11-beta-hydroxylase; 17α-OH = 17-alpha-hydroxylase

Gonadal Malignancy Risk

Dysgenetic gonads, particularly those containing Y chromosome material in individuals with female or ambiguous phenotype, carry significant malignancy risk. Understanding this risk guides surgical decision-making.

Condition	Malignancy Risk	Timing	Management Consideration
Complete Gonadal Dysgenesis (Swyer)	15-35%	Can occur in childhood	Early gonadectomy recommended
Partial Gonadal Dysgenesis	15-40%	Variable	Early gonadectomy for streak gonads; individualized for dysgenetic testes
Mixed Gonadal Dysgenesis	15-30%	Often early	Remove streak gonad; monitor scrotal testis; gonadoblastoma precursor risk
Complete Androgen Insensitivity Syndrome	2-5%	Usually postpubertal	May delay gonadectomy until after puberty; regular monitoring
Partial Androgen Insensitivity Syndrome	15-50%	Variable	Higher risk than CAIS; earlier consideration of gonadectomy
Ovotesticular DSD	3-5%	Lower than dysgenesis	Risk mainly in streak or dysgenetic portions; preserve functional tissue when possible

3. History Taking

A comprehensive approach to eliciting the history in suspected disorders of sex development

Red Flags — Require Urgent Evaluation

Signs of adrenal crisis — Poor feeding, vomiting, lethargy, dehydration (suggests salt-wasting CAH)
Hypoglycemia — May indicate cortisol deficiency or panhypopituitarism
Hyponatremia/Hyperkalemia — Electrolyte pattern of mineralocorticoid deficiency
Hyperpigmentation — Elevated ACTH suggests adrenal insufficiency

Bilateral non-palpable gonads — Must exclude 46,XX CAH with potential for adrenal crisis
Family history of neonatal death — Undiagnosed CAH may have caused prior sibling deaths
Maternal virilization during pregnancy — Suggests fetal androgen-producing condition or aromatase deficiency
Inguinal mass in phenotypic female — May represent testis; suggests androgen insensitivity or other 46,XY DSD

Timing of Salt-Wasting Crisis

Salt-wasting congenital adrenal hyperplasia typically presents between days 7-14 of life. The first few days may be relatively asymptomatic due to residual maternal steroids and placental function. Maintain high vigilance during this critical window. Male infants with CAH may have normal-appearing genitalia and present only with adrenal crisis — a diagnostic challenge.

Systematic History: The “GENITAL” Approach

Use the mnemonic “GENITAL” to ensure comprehensive history taking in suspected disorders of sex development:

G — Gestational and birth history: Prenatal findings, medications, maternal health during pregnancy
E — Examination findings at birth: What exactly was noted? Who first identified the concern?
N — Neonatal course: Feeding, weight gain, voiding pattern, any signs of illness
I — Inheritance and family history: Consanguinity, affected relatives, unexplained neonatal deaths, infertility
T — Treatments and medications: Any medications given to mother during pregnancy or to infant
A — Associated anomalies: Other congenital abnormalities that may suggest syndromic cause
L — Laboratory results: Any testing already performed (newborn screening, karyotype, hormones)

Prenatal and Birth History

The prenatal history is particularly important in DSD evaluation as many conditions have identifiable prenatal features or exposures.

Historical Element	Key Questions	Clinical Significance
Prenatal ultrasound findings	“Was sex determined on ultrasound? Were there any concerns about the genitalia?”	Discordance between prenatal sex assignment and postnatal appearance suggests DSD; prenatal identification allows earlier preparation
Prenatal genetic testing	“Was amniocentesis, CVS, or cell-free DNA testing performed? What were the results?”	Known karyotype expedites postnatal workup; discordance between genetic sex and phenotype is diagnostic clue
Maternal medications	“Did you take any medications during pregnancy, including hormones, fertility treatments, or herbal supplements?”	Progestins, danazol, and some fertility treatments can cause virilization of 46,XX fetus
Maternal virilization	“Did you notice any unusual hair growth, acne, voice changes, or clitoral enlargement during pregnancy?”	Suggests androgen-secreting tumor (luteoma, arrhenoblastoma), maternal CAH, or aromatase deficiency
Assisted reproductive technology	“Was this pregnancy conceived naturally or with fertility treatment? What type?”	Some ART protocols use hormones that may affect fetal development; also relevant for genetic counseling
Gestational age and birth weight	“What was the gestational age at delivery? What was the birth weight?”	Intrauterine growth restriction may accompany some syndromic causes; prematurity affects genital appearance

Neonatal Course

Careful assessment of the neonatal period helps identify signs of underlying metabolic or endocrine dysfunction.

Assessment Area	Key Questions	What It May Indicate
Feeding	“How is the baby feeding? Any vomiting, poor suck, or refusing feeds?”	Poor feeding and vomiting are early signs of adrenal crisis; hypoglycemia may cause lethargy affecting feeds
Weight trajectory	“Has the baby lost weight since birth? More than expected? Failure to regain birth weight?”	Excessive weight loss suggests salt-wasting; normal is up to 10% loss with regain by day 10-14
Voiding pattern	“Where does the baby urinate from? Is there a single opening or multiple? Any difficulty with urinary stream?”	Single perineal opening suggests urogenital sinus; abnormal stream may indicate urethral abnormality
Skin color	“Have you noticed any darkening of the skin, especially in the genital area, nipples, or skin creases?”	Hyperpigmentation indicates elevated ACTH — classic sign of primary adrenal insufficiency/CAH
Activity level	“Is the baby alert and active? Any episodes of unusual sleepiness or floppiness?”	Lethargy may indicate hypoglycemia, hyponatremia, or impending adrenal crisis
Jaundice	“Has the baby been jaundiced? Is jaundice prolonged beyond 2 weeks?”	Prolonged conjugated jaundice may indicate panhypopituitarism with cortisol and thyroid deficiency

Family History

Family history is crucial as many DSD conditions are inherited. A detailed three-generation pedigree should be obtained.

Family History Element	Specific Questions to Ask	Conditions Suggested
Consanguinity	“Are you and your partner related by blood? Are your families from the same village or community?”	Increases risk of autosomal recessive conditions: CAH, 5-alpha reductase deficiency, 17-beta-HSD deficiency
Unexplained neonatal deaths	“Have there been any infant deaths in either family, especially in the first few weeks of life?”	Undiagnosed salt-wasting CAH — male infants may appear normal and die of “sepsis” or “SIDS”
DSD or genital surgery	“Has anyone in the family had surgery on their genitals as a baby? Anyone with ambiguous genitalia?”	Previous undiagnosed DSD in family; autosomal recessive or X-linked conditions
Infertility	“Are there family members who have been unable to have children? Any aunts without children?”	Maternal aunts with primary amenorrhea suggest X-linked androgen insensitivity syndrome
Primary amenorrhea	“Are there women in the family who never had periods?”	Androgen insensitivity syndrome, gonadal dysgenesis, Müllerian agenesis
Precocious or delayed puberty	“Did anyone in the family have very early or very late puberty?”	CAH (precocious puberty), androgen synthesis defects (delayed puberty)
Adrenal insufficiency	“Does anyone take steroid medications for adrenal problems?”	Known CAH or other adrenal conditions in family
Ethnic background	“What is your family’s ethnic background? Where are your ancestors from?”	5-alpha reductase deficiency clusters in Dominican Republic, Papua New Guinea, Turkey; CAH varies by ethnicity

Clinical Pearl: The “Hidden” Family History

Families may not volunteer relevant history due to shame, secrecy, or lack of awareness. Specifically ask about: aunts who “couldn’t have children” or “never married” (possible CAIS), babies who “died suddenly” in the first weeks (undiagnosed CAH), relatives who had “corrective surgery” as infants (previous DSD), and family members with “hormone problems” or taking “steroids for life” (CAH on treatment). These indirect questions often reveal crucial diagnostic information.

Targeted Questions by Suspected Etiology

Suspected Condition	Key Historical Features	Specific Questions to Ask
Congenital Adrenal Hyperplasia (21-hydroxylase deficiency)	Virilized 46,XX infant; may have salt-wasting; hyperpigmentation	“Any vomiting or poor feeding starting around 1-2 weeks? Any darkening of the skin? Family history of CAH or unexplained infant deaths?”
Androgen Insensitivity Syndrome	46,XY with female or ambiguous genitalia; inguinal mass; X-linked inheritance	“Were any lumps felt in the groin during pregnancy or at birth? Any maternal aunts who never had periods or couldn’t have children?”
5-Alpha Reductase Deficiency	46,XY with female/ambiguous genitalia at birth; autosomal recessive; ethnic clustering	“Is there consanguinity in the family? What is the family’s ethnic/geographic origin? Any relatives who were raised as girls but became men at puberty?”
Gonadal Dysgenesis	Variable phenotype; may have streak gonads; Turner features if 45,X present	“Were there any abnormalities noted on prenatal ultrasound such as neck swelling, heart defects, or kidney problems?”
Mixed Gonadal Dysgenesis	45,X/46,XY mosaicism; asymmetric gonads; variable phenotype	“Is there asymmetry in the genital appearance? One gonad palpable and one not?”
Maternal Androgen Exposure	History of medication or tumor during pregnancy; maternal virilization	“Did you take any hormones, steroids, or fertility medications during pregnancy? Did you notice any changes in your body — increased hair, acne, voice deepening?”
Aromatase Deficiency	Maternal virilization that resolves postpartum; virilized 46,XX infant	“Did you develop masculine features during pregnancy that improved after delivery? Any acne, excess hair, or voice changes?”

Associated Anomalies to Inquire About

DSD may occur as part of syndromic conditions. Ask specifically about other congenital anomalies.

Anomalies Suggesting Syndromic DSD

Cardiac defects — WAGR syndrome, Smith-Lemli-Opitz syndrome, Turner syndrome
Renal anomalies — Denys-Drash syndrome, WAGR syndrome, Frasier syndrome
Aniridia — WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, intellectual disability)
Intellectual disability — Smith-Lemli-Opitz syndrome, WAGR syndrome
Limb anomalies — Hand-foot-genital syndrome, Aarskog syndrome
Cleft lip/palate — Multiple syndromic associations

Questions to Ask

“Were any heart problems detected before or after birth?”
“Were the kidneys normal on ultrasound?”
“Are the eyes normal? Any problems with the iris?”
“Are there any concerns about the baby’s development or alertness?”
“Are the hands and feet normal? All fingers and toes present?”
“Is the palate intact? Any feeding difficulties suggesting cleft?”

Psychosocial Assessment

Understanding the family’s psychosocial context is essential for providing appropriate support and counseling.

Assessment Area	Questions to Consider	Why It Matters
Understanding of the situation	“What have you been told so far? What is your understanding of what’s happening?”	Identifies misconceptions; establishes baseline for education
Emotional response	“How are you coping with this? What are your biggest concerns right now?”	Allows expression of fear, grief, guilt; identifies need for psychological support
Support systems	“Who else knows about this? Do you have family or friends who can support you?”	Identifies isolation versus support; guides involvement of social work
Cultural and religious factors	“Are there cultural or religious considerations we should be aware of?”	Some cultures have specific beliefs about gender; affects family dynamics and decisions
Information sharing preferences	“Who else would you like us to speak with? How would you like information shared?”	Respects family autonomy; ensures appropriate confidentiality
Birth registration concerns	“Have you been asked about the birth certificate? Do you have questions about registration?”	Addresses practical concern; most jurisdictions allow delayed registration

4. Physical Examination

A systematic approach to examining the infant with ambiguous genitalia

Examination Principles: The physical examination of an infant with suspected DSD should be thorough, systematic, and sensitively performed. Examine the infant in a warm, well-lit environment with parents present if they wish. Explain findings as you examine. Document carefully using standardized terminology and measurements. The genital examination should be performed by experienced clinicians to minimize repeated examinations.

General Inspection

Begin with overall assessment before focusing on the genitalia. Many DSD conditions have associated features that provide diagnostic clues.

Assessment	What to Look For	Clinical Significance
General appearance	Alert versus lethargic; well versus unwell; any dysmorphic features	Lethargy may indicate adrenal crisis or hypoglycemia; dysmorphism suggests syndromic cause
Growth parameters	Weight, length, head circumference; plot on appropriate growth charts	IUGR associated with some syndromic causes; weight loss may indicate salt-wasting
Skin	Hyperpigmentation (especially areolae, genitalia, skin creases); jaundice	Hyperpigmentation suggests elevated ACTH (CAH); prolonged jaundice suggests hypopituitarism
Hydration status	Skin turgor, mucous membranes, fontanelle, capillary refill	Dehydration may indicate evolving salt-wasting crisis
Facies	Dysmorphic features; midline defects; Turner syndrome features	Low-set ears, webbed neck (Turner); midface hypoplasia (Smith-Lemli-Opitz); midline defects (hypopituitarism)

Vital Signs

Vital Sign	Normal Range (Term Neonate)	Abnormalities to Note	Clinical Significance
Heart Rate	100-160 beats per minute	Tachycardia; bradycardia	Tachycardia with dehydration or shock; bradycardia with severe hypoglycemia
Respiratory Rate	30-60 breaths per minute	Tachypnea; labored breathing	Tachypnea may indicate metabolic acidosis in adrenal crisis
Blood Pressure	Systolic 60-90 mmHg (term)	Hypotension; hypertension	Hypotension in adrenal crisis; hypertension in 11-beta-hydroxylase or 17-alpha-hydroxylase deficiency
Temperature	36.5-37.5°C	Hypothermia; hyperthermia	Hypothermia may accompany adrenal insufficiency; fever suggests infection
Oxygen Saturation	>95%	Desaturation	May indicate associated cardiac anomaly
Blood Glucose	>2.6 mmol/L (>45 mg/dL)	Hypoglycemia	Suggests cortisol deficiency; associated with hypopituitarism, CAH

Systematic Examination for Associated Anomalies

Head and Neck

Eyes: Check for aniridia (WAGR syndrome), cataracts, coloboma
Ears: Low-set or posteriorly rotated ears suggest chromosomal anomaly
Palate: Cleft palate or high-arched palate
Neck: Webbing, low posterior hairline, excess nuchal skin (Turner syndrome features)
Midline: Single central incisor, cleft lip — may indicate midline defect with hypopituitarism

Cardiovascular

Murmurs: Congenital heart disease associated with Turner syndrome, CHARGE, Smith-Lemli-Opitz
Femoral pulses: Coarctation of aorta (Turner syndrome)
Four-limb blood pressures: If coarctation suspected

Abdominal

Masses: Palpable kidneys (horseshoe kidney, hydronephrosis); adrenal masses rare
Hepatomegaly: May occur with congestive heart failure from associated cardiac anomalies
Umbilicus: Hernia; omphalocele (associated with some syndromes)

Extremities

Hands and feet: Syndactyly (Smith-Lemli-Opitz); short fourth metacarpal (Turner syndrome)
Lymphedema: Dorsal hand and foot edema in Turner syndrome
Digits: Polydactyly, brachydactyly associated with various syndromes

Genital Examination: Systematic Approach

The genital examination is the cornerstone of DSD evaluation. Use consistent terminology and document precise measurements.

Documentation Standards

Use objective, descriptive language rather than terms like “normal male” or “normal female.” Document: phallus length and width, position of urethral meatus, degree of labioscrotal fusion, presence and location of palpable gonads, rugosity and pigmentation of labioscrotal folds, number and position of perineal openings. Photography (with parental consent) provides valuable documentation for the multidisciplinary team and reduces need for repeated examinations.

Phallus Assessment

Measurement	Technique	Normal Values	Clinical Significance
Stretched penile length	Stretch phallus gently; measure from pubic bone to tip of glans using rigid ruler; depress suprapubic fat pad	Term male: 2.5-4.5 cm (mean 3.5 cm); Micropenis: less than 2.5 cm (-2.5 SD)	Micropenis suggests androgen deficiency or insensitivity; normal length with hypospadias has different implications than micropenis
Clitoral length	Measure from pubic bone to tip; document width also	Term female: less than 9 mm length; less than 6 mm width	Clitoromegaly (greater than 9 mm) indicates androgen exposure; degree correlates with timing and amount of exposure
Phallus width/diameter	Measure at widest point of shaft	Term male: approximately 1.1 cm diameter	Discordantly small diameter with normal length suggests specific conditions
Chordee	Observe curvature of phallus, particularly on erection (may occur spontaneously in neonates)	Absent	Ventral chordee common with hypospadias; suggests incomplete masculinization

Urethral Meatus Assessment

Finding	Description	Clinical Significance
Normal male position	At tip of glans penis (glanular)	Normal male development
Hypospadias — Glanular/Coronal	On glans but not at tip, or at corona	Mild hypospadias; usually isolated but evaluate for other DSD features
Hypospadias — Penile shaft	On ventral penile shaft (distal, mid, or proximal)	Moderate hypospadias; higher likelihood of associated DSD, especially if with cryptorchidism
Hypospadias — Penoscrotal/Scrotal	At junction of penis and scrotum or on scrotum	Severe hypospadias; high association with DSD; requires full evaluation
Hypospadias — Perineal	On perineum	Severe undervirilization; DSD evaluation mandatory
Single perineal opening	Urethral and vaginal openings share common channel (urogenital sinus)	Indicates persistent urogenital sinus; seen in virilized 46,XX and undervirilized 46,XY

Labioscrotal Fold Assessment

Finding	Description	Significance
Completely unfused	Two separate labia majora with no midline fusion	Female pattern; no androgen effect on labioscrotal folds
Posterior fusion only	Fusion limited to posterior portion of labioscrotal folds	Mild virilization (Prader II); suggests limited androgen exposure
Complete fusion	Fully fused midline structure resembling scrotum	Significant androgen exposure; Prader III-V in 46,XX; typical male in 46,XY
Bifid scrotum	Scrotum divided into two distinct halves	Incomplete masculinization; associated with severe hypospadias
Rugosity	Wrinkling/corrugation of labioscrotal skin	Rugosity indicates androgen effect; smooth suggests minimal androgen exposure
Hyperpigmentation	Increased pigmentation of labioscrotal folds	Suggests elevated ACTH; classic for CAH

Gonad Assessment

Systematic palpation for gonads is crucial. The presence and location of palpable gonads significantly narrows the differential diagnosis.

Finding	Technique	Clinical Implications
Bilateral palpable gonads in labioscrotal folds	Palpate labioscrotal folds from inguinal canal downward; gonads feel firm and ovoid	Almost certainly testes (ovaries rarely descend); likely 46,XY DSD or ovotesticular DSD
Unilateral palpable gonad	One gonad palpable; carefully examine contralateral side and inguinal region	Asymmetric development suggests mixed gonadal dysgenesis or ovotesticular DSD
Bilateral non-palpable gonads	No gonads palpable in labioscrotal folds or inguinal canals	Consider 46,XX DSD (CAH most likely); could be bilateral cryptorchidism; requires urgent workup
Inguinal gonad/mass	Palpate along inguinal canal; may be mobile	Inguinal testis; in phenotypic female suggests AIS; may also represent inguinal hernia containing gonad
Gonad size	Estimate size; use orchidometer if available (Prader beads)	Term male testis approximately 1.5-2 cm length; small testes may indicate dysgenesis

Clinical Pearl: The Palpable Gonad Rule

A palpable gonad in the labioscrotal fold or inguinal canal is almost always a testis or ovotestis — ovaries virtually never descend to these locations. Therefore:

Bilateral palpable gonads essentially excludes 46,XX DSD (such as CAH) — these infants have ovaries which remain intra-abdominal
Unilateral palpable gonad suggests asymmetric gonadal development (mixed gonadal dysgenesis, ovotesticular DSD)
A phenotypic female with bilateral inguinal masses likely has androgen insensitivity syndrome with intra-abdominal or inguinal testes

This simple examination finding dramatically narrows the differential diagnosis.

External Masculinization Score (EMS)

The External Masculinization Score provides a standardized, objective measure of the degree of masculinization. It is particularly useful for monitoring and comparing findings over time.

Feature	Score 0	Score 1	Score 2	Score 3
Urethral meatus position	Perineal/absent	Penoscrotal to midshaft	Midshaft to glanular	Normal glanular
Labioscrotal fusion	Absent (unfused)	Posterior fusion only	Fused throughout	Fully fused with midline raphe
Right gonad	Non-palpable	Inguinal	High scrotal	Low scrotal
Left gonad	Non-palpable	Inguinal	High scrotal	Low scrotal

Interpretation: Total score ranges from 0 (completely female phenotype) to 12 (completely male phenotype). Micropenis adds complexity but does not change the score. EMS helps standardize documentation and track changes with any hormonal treatment.

Expected Examination Findings by Condition

Condition	Phallus	Urethral Meatus	Labioscrotal Folds	Gonads	Other Features
21-Hydroxylase Deficiency (46,XX)	Clitoromegaly (variable)	Urogenital sinus; variable position	Posterior fusion; rugosity; hyperpigmentation	Not palpable (ovaries)	Hyperpigmentation of areolae, skin creases; signs of salt-wasting if present
Complete Androgen Insensitivity Syndrome (46,XY)	Normal female clitoris	Normal female urethral position	Normal labia majora	Inguinal or labial masses (testes); may be intra-abdominal	Phenotypically female; blind vaginal pouch; inguinal hernia common
Partial Androgen Insensitivity Syndrome (46,XY)	Variable — micropenis to clitoromegaly	Hypospadias (variable degree)	Partial fusion; variable	May be palpable (descended or inguinal)	Wide phenotypic spectrum
5-Alpha Reductase Deficiency (46,XY)	Small phallus/clitoromegaly	Perineoscrotal hypospadias or urogenital sinus	Bifid scrotum or partial fusion	Usually palpable (inguinal or labioscrotal)	Blind vaginal pouch; virilization at puberty expected
Mixed Gonadal Dysgenesis (45,X/46,XY)	Variable	Variable hypospadias	Asymmetric	Asymmetric — one palpable (dysgenetic testis), one not (streak gonad)	Asymmetry is hallmark; may have Turner features
Ovotesticular DSD	Variable	Variable	Variable; may be asymmetric	Variable; ovotestis may be palpable	Asymmetry common; may have functioning ovarian and testicular tissue
Complete Gonadal Dysgenesis (Swyer Syndrome, 46,XY)	Normal female clitoris	Normal female	Normal labia	Not palpable (streak gonads)	Phenotypically female; uterus present; usually diagnosed at puberty with primary amenorrhea

Important Teaching Point: When Examination Appears Normal

Some DSD conditions present with apparently normal external genitalia and are not diagnosed until later:

46,XY males with CAH (non-salt-wasting): May appear completely normal; diagnosed only through newborn screening or family history
Complete Androgen Insensitivity Syndrome: Phenotypically normal female; diagnosed when inguinal hernia found to contain testis, or at puberty with amenorrhea
Swyer Syndrome: Normal female phenotype; diagnosed at puberty with lack of development and primary amenorrhea
Mild 5-alpha reductase deficiency: May appear female at birth; dramatic virilization at puberty

A normal genital examination does not exclude DSD — clinical suspicion and appropriate follow-up remain essential.

Rectal Examination (When Indicated)

Rectal examination is not routine but may be helpful to palpate for a uterus in select cases. A cervix may be palpable anteriorly through the rectal wall. This is typically deferred to experienced examiners and often replaced by pelvic ultrasound.

Documentation Checklist

Essential elements to document in every examination:

Stretched phallic length (in millimeters or centimeters)
Phallic width
Position of urethral meatus
Presence and degree of chordee
Degree of labioscrotal fusion (none, posterior only, complete)
Rugosity of labioscrotal folds
Hyperpigmentation (present/absent, distribution)
Number of perineal openings
Right gonad: location (non-palpable, inguinal, labioscrotal) and size
Left gonad: location and size
External Masculinization Score (0-12)
Prader stage (if 46,XX suspected)
Associated anomalies identified
Photographs obtained (with consent) — yes/no

5. Differential Diagnosis

Systematic approach organized by karyotype, probability, and clinical features

The differential diagnosis of ambiguous genitalia is best organized by karyotype, as this determines the underlying pathophysiology and guides management. The initial approach should focus on identifying life-threatening conditions (particularly salt-wasting congenital adrenal hyperplasia) while systematically working through the diagnostic possibilities.

Step-by-Step Diagnostic Approach:

Step 1: Stabilize and screen for emergencies — Check electrolytes, glucose, 17-hydroxyprogesterone; monitor for adrenal crisis
Step 2: Determine karyotype — Rapid FISH for X and Y chromosomes (results in 24-48 hours); full karyotype follows
Step 3: Assess gonad presence and location — Physical examination and pelvic ultrasound
Step 4: Hormonal evaluation — Based on karyotype and clinical findings
Step 5: Imaging and specialized testing — As indicated by initial results

Initial Diagnostic Algorithm Based on Gonad Palpability

The presence or absence of palpable gonads provides immediate diagnostic guidance while awaiting karyotype results.

Gonad Finding	Most Likely Diagnosis	Immediate Priority	Key Investigations
Bilateral non-palpable gonads	46,XX DSD (CAH most common) until proven otherwise	URGENT: Exclude salt-wasting CAH — potential adrenal crisis	17-OHP, electrolytes, glucose, karyotype, pelvic ultrasound
Unilateral palpable gonad	Mixed gonadal dysgenesis; ovotesticular DSD	Karyotype (likely mosaic); assess for Müllerian structures	Karyotype, ultrasound, gonadal biopsy may be needed
Bilateral palpable gonads	46,XY DSD (undervirilization); ovotesticular DSD	Less urgent for adrenal crisis; systematic hormonal evaluation	Karyotype, testosterone, DHT, AMH, hCG stimulation test

Critical Point: Bilateral Non-Palpable Gonads

An infant with ambiguous genitalia and bilateral non-palpable gonads should be considered to have salt-wasting congenital adrenal hyperplasia until proven otherwise. This is because:

46,XX CAH is the most common cause of ambiguous genitalia
Ovaries do not descend — non-palpable gonads suggest ovaries (46,XX)
75% of classic 21-hydroxylase deficiency is salt-wasting
Salt-wasting crisis typically occurs at 7-14 days of life and can be fatal

These infants require close monitoring of electrolytes, glucose, and feeding until CAH is excluded.

46,XX DSD: Virilization of Female Fetus

In 46,XX DSD, genetically female infants have been exposed to excess androgens, resulting in virilization of the external genitalia. The ovaries and Müllerian structures (uterus, fallopian tubes, upper vagina) are typically normal.

Probability	Condition	Frequency	Key Features	Diagnostic Clues
COMMON	21-Hydroxylase Deficiency (CAH)	90-95% of CAH; 1:15,000 births	Variable virilization (Prader I-V); 75% salt-wasting; hyperpigmentation	Elevated 17-OHP (markedly); non-palpable gonads; uterus on ultrasound; may have family history
LESS COMMON	11-Beta-Hydroxylase Deficiency	5-8% of CAH	Virilization similar to 21-OHD; hypertension (may develop later); hypokalemia	Elevated 11-deoxycortisol and 11-deoxycorticosterone; 17-OHP mildly elevated
LESS COMMON	3-Beta-Hydroxysteroid Dehydrogenase Deficiency	Rare	Mild virilization in 46,XX (from DHEA); salt-wasting common	Elevated 17-hydroxypregnenolone and DHEA; low cortisol and aldosterone
UNCOMMON	Aromatase Deficiency	Very rare	Virilization; maternal virilization during pregnancy (resolves postpartum)	Elevated androgens; undetectable estrogens; maternal history of virilization
UNCOMMON	P450 Oxidoreductase Deficiency	Rare	Variable virilization; may have skeletal anomalies (Antley-Bixler syndrome features)	Combined pattern of steroid abnormalities; skeletal survey if suspected
UNCOMMON	Maternal Androgen Exposure	Rare (decreasing with awareness)	Virilization without adrenal dysfunction; no salt-wasting risk	History of maternal medication (progestins, danazol) or androgen-secreting tumor; normal 17-OHP
UNCOMMON	Glucocorticoid Receptor Gene Mutations	Very rare	Cortisol resistance leading to ACTH elevation and adrenal androgen excess	Elevated cortisol without Cushingoid features; elevated androgens

46,XY DSD: Undervirilization of Male Fetus

In 46,XY DSD, genetically male infants have insufficient masculinization due to disorders of gonadal development, androgen synthesis, or androgen action. The phenotype ranges from completely female to ambiguous to mildly undervirilized male.

Disorders of Gonadal Development

Probability	Condition	Key Features	Diagnostic Clues
LESS COMMON	Partial Gonadal Dysgenesis	Variable ambiguity; dysgenetic testes with reduced function; high malignancy risk	Low testosterone; elevated gonadotropins; dysgenetic gonads on imaging/biopsy; may have Müllerian remnants
UNCOMMON	Complete Gonadal Dysgenesis (Swyer Syndrome)	Female external genitalia; streak gonads; presents at puberty with amenorrhea	46,XY with female phenotype; uterus present; elevated gonadotropins at pubertal age
UNCOMMON	Gonadal Regression Syndrome (Vanishing Testes)	Variable phenotype depending on timing of testicular loss; anorchia	46,XY; no palpable gonads; no testicular tissue on imaging; low AMH; variable masculinization
UNCOMMON	SF1 (NR5A1) Mutations	Spectrum from complete female to ambiguous; may have adrenal insufficiency	Variable testosterone production; may have primary adrenal insufficiency; family history

Disorders of Androgen Synthesis

Probability	Condition	Key Features	Diagnostic Clues
LESS COMMON	5-Alpha Reductase Type 2 Deficiency	Female or ambiguous at birth; dramatic virilization at puberty; often consanguinity	Normal/elevated testosterone; low DHT; elevated T:DHT ratio (>20); ethnic clustering
LESS COMMON	17-Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency	Female or ambiguous at birth; virilization at puberty; similar to 5-ARD clinically	Elevated androstenedione; low testosterone; elevated A:T ratio; virilization at puberty
UNCOMMON	17-Alpha-Hydroxylase/17,20-Lyase Deficiency	Female or ambiguous; hypertension; hypokalemia; absent puberty	Low cortisol and sex steroids; elevated mineralocorticoids; hypertension
UNCOMMON	StAR Protein Deficiency (Lipoid CAH)	Female phenotype in 46,XY; severe adrenal insufficiency; lipid-laden adrenals	All steroid hormones low; severe salt-wasting; adrenal calcification on imaging
UNCOMMON	Leydig Cell Hypoplasia/Aplasia	Female or ambiguous; Leydig cells absent or non-functional	Low testosterone that does not rise with hCG stimulation; LH elevated
UNCOMMON	3-Beta-HSD Type 2 Deficiency (in 46,XY)	Undervirilization; salt-wasting; affects adrenal and gonadal steroidogenesis	Elevated DHEA and 17-hydroxypregnenolone; salt-wasting

Disorders of Androgen Action

Probability	Condition	Key Features	Diagnostic Clues
COMMON	Partial Androgen Insensitivity Syndrome (PAIS)	Wide phenotypic spectrum; micropenis to clitoromegaly; hypospadias common	Normal or elevated testosterone and LH; androgen receptor gene mutation (not always found)
LESS COMMON	Complete Androgen Insensitivity Syndrome (CAIS)	Female external genitalia; inguinal testes; presents with hernia or amenorrhea	46,XY with female phenotype; elevated testosterone; no uterus; testes on imaging

Other 46,XY DSD

Condition	Key Features	Diagnostic Clues
Persistent Müllerian Duct Syndrome	Male phenotype with cryptorchidism; uterus and fallopian tubes present	Usually found incidentally during surgery for cryptorchidism or hernia; low/absent AMH
Isolated Hypospadias	Hypospadias without other DSD features; common (1:300 males)	Normal hormones; no other genital ambiguity; often familial
Isolated Micropenis	Small but normally formed penis; may be idiopathic or part of hypogonadism	Investigate for hypogonadotropic hypogonadism, growth hormone deficiency

Sex Chromosome DSD

Probability	Condition	Karyotype	Key Features	Diagnostic Clues
LESS COMMON	Mixed Gonadal Dysgenesis	45,X/46,XY (most common)	Asymmetric gonads (streak + dysgenetic testis); variable phenotype; Turner features may be present	Asymmetry on exam; karyotype shows mosaicism; high gonadal malignancy risk
LESS COMMON	Ovotesticular DSD	46,XX (most common); 46,XY; 46,XX/46,XY	Both ovarian and testicular tissue present; variable phenotype	May have ovotestis; asymmetric gonads; definitive diagnosis requires gonadal biopsy
UNCOMMON	46,XX Testicular DSD (XX Male)	46,XX	Male phenotype; small testes; infertility; usually diagnosed in adulthood	SRY translocation to X chromosome in most cases; male phenotype with 46,XX
UNCOMMON	45,X/46,XY (Turner Variant)	45,X/46,XY mosaicism	Spectrum from Turner syndrome to male with short stature to ambiguous genitalia	Turner features may be present; gonadal evaluation essential
UNCOMMON	47,XXY (Klinefelter) Variants	47,XXY or mosaic	Usually male phenotype; may have small testes, hypospadias; presents later with infertility	Rarely presents with ambiguous genitalia; small firm testes; gynecomastia at puberty

Anatomical Approach to Differential Diagnosis

Androgen Excess (Virilization)

Fetal source:

• 21-Hydroxylase deficiency

• 11-Beta-hydroxylase deficiency

• 3-Beta-HSD deficiency

Fetoplacental:

• Aromatase deficiency

Maternal:

• Luteoma of pregnancy

• Exogenous androgens

Androgen Deficiency (Undervirilization)

Synthesis defects:

• 17-Alpha-hydroxylase deficiency

• 17-Beta-HSD deficiency

• StAR deficiency

Gonadal dysfunction:

• Leydig cell hypoplasia

• Gonadal dysgenesis

• Testicular regression

Androgen Resistance

Receptor defects:

• Complete AIS (CAIS)

• Partial AIS (PAIS)

Post-receptor:

• Rare signaling defects

Conversion defect:

• 5-Alpha reductase deficiency

Gonadal Development Disorders

Dysgenesis:

• Complete gonadal dysgenesis

• Partial gonadal dysgenesis

• Mixed gonadal dysgenesis

Other:

• Ovotesticular DSD

• Testicular regression

• SF1 mutations

Maternal Exposures and Medications Causing Virilization

Exposure	Mechanism	Characteristics	Outcome
Progestins (older synthetic)	Androgenic activity of certain progestins	First trimester exposure; dose-dependent effect	Mild virilization; no ongoing hormonal abnormality
Danazol	Synthetic androgen used for endometriosis	Potent virilizing effect; now contraindicated in pregnancy	Significant virilization possible; no ongoing abnormality
Testosterone/Anabolic steroids	Direct androgen effect	May be from supplements, compounded medications, partner’s topical testosterone	Variable virilization; no ongoing abnormality
Luteoma of pregnancy	Ovarian tumor producing androgens	Maternal virilization during pregnancy; resolves postpartum	Virilization of female fetus; no ongoing abnormality
Maternal CAH (untreated or undertreated)	Maternal androgen excess	Mother has CAH; inadequate suppression during pregnancy	Virilization of female fetus; fetus may also have CAH (25% risk if father carrier)
Aromatase inhibitors	Prevent conversion of androgens to estrogens	Used for breast cancer or fertility; contraindicated in pregnancy	Virilization possible

Quick Reference: “If You See This, Think This First”

Clinical Finding	Think This First	Immediate Action
Virilized infant + bilateral non-palpable gonads + hyperpigmentation	21-Hydroxylase deficiency (CAH)	URGENT: Check 17-OHP, electrolytes; monitor for salt-wasting crisis
Phenotypic female + bilateral inguinal masses	Complete androgen insensitivity syndrome	Karyotype; pelvic ultrasound (no uterus expected); testosterone level
Ambiguous genitalia + asymmetric gonads	Mixed gonadal dysgenesis or ovotesticular DSD	Karyotype (likely mosaic); ultrasound; gonadal evaluation
Undervirilized 46,XY + consanguinity + ethnic clustering	5-Alpha reductase deficiency or 17-Beta-HSD deficiency	Testosterone, DHT, androstenedione levels; T:DHT ratio
Ambiguous genitalia + hypertension	11-Beta-hydroxylase deficiency or 17-Alpha-hydroxylase deficiency	Steroid profile; electrolytes; blood pressure monitoring
Virilized infant + maternal virilization during pregnancy	Aromatase deficiency or maternal androgen-secreting tumor	Maternal history; estrogen and androgen levels; 17-OHP (to exclude CAH)
Undervirilized 46,XY + uterus present	Disorders of gonadal development; persistent Müllerian duct syndrome	AMH level; gonadal imaging; testosterone and gonadotropins
46,XY + female phenotype + no Müllerian structures	Complete AIS or complete gonadal dysgenesis	AMH, testosterone (high in CAIS, low in dysgenesis); gonadal imaging
Ambiguous genitalia + severe adrenal insufficiency + no virilization	StAR deficiency (lipoid CAH)	All steroids low; adrenal imaging (lipid-laden adrenals)

Syndromic Causes to Consider

Syndrome	Key Associated Features	DSD Phenotype
WAGR Syndrome	Wilms tumor, Aniridia, Genitourinary anomalies, Intellectual disability	46,XY DSD with gonadal dysgenesis; cryptorchidism; hypospadias
Denys-Drash Syndrome	Nephropathy (early renal failure), Wilms tumor	46,XY DSD with gonadal dysgenesis; ambiguous to female phenotype
Frasier Syndrome	Focal segmental glomerulosclerosis, gonadoblastoma risk	46,XY with female phenotype; streak gonads
Smith-Lemli-Opitz Syndrome	Intellectual disability, 2-3 toe syndactyly, multiple anomalies	46,XY undervirilization; genital ambiguity common in males
Campomelic Dysplasia	Bowed long bones, respiratory compromise, Pierre Robin sequence	75% of 46,XY have female or ambiguous genitalia; SOX9 mutation
Antley-Bixler Syndrome	Craniosynostosis, radiohumeral synostosis, femoral bowing	Ambiguous genitalia; P450 oxidoreductase deficiency in some

6. Diagnostic Investigations

A systematic, karyotype-guided approach to investigating ambiguous genitalia

The investigation of ambiguous genitalia should be systematic, prioritizing the exclusion of life-threatening conditions while working toward a definitive diagnosis. The approach is guided by clinical findings and karyotype results. All investigations should be performed by or in consultation with a pediatric endocrinologist experienced in DSD evaluation.

Timing Considerations

Critical window for hormonal assessment: Many hormonal tests are most informative during the “mini-puberty” period (first 3-6 months of life) when the hypothalamic-pituitary-gonadal axis is active. After this period, gonadotropins and sex steroids decline to prepubertal levels, making interpretation more difficult. Stimulation tests may then be required.

17-OHP timing: 17-hydroxyprogesterone should be measured after 36 hours of life to avoid false positives from normal postnatal elevation and stress-related increases.

Immediate Investigations (Day 1-2)

These investigations should be performed urgently in all infants with ambiguous genitalia to identify life-threatening conditions and guide initial management.

Investigation	Purpose	What to Look For	Practical Points
Serum electrolytes (sodium, potassium)	Detect salt-wasting	Hyponatremia (Na less than 130), hyperkalemia (K greater than 6.0)	May be normal initially; repeat daily for first 2 weeks if CAH suspected; crisis typically days 7-14
Blood glucose	Detect hypoglycemia (cortisol deficiency)	Glucose less than 2.6 mmol/L (less than 45 mg/dL)	Hypoglycemia suggests adrenal insufficiency; also seen in hypopituitarism
17-Hydroxyprogesterone (17-OHP)	Screen for 21-hydroxylase deficiency	Markedly elevated (typically greater than 300 nmol/L or greater than 10,000 ng/dL in classic CAH)	Draw after 36-48 hours of life; stress/prematurity cause mild elevation; use gestational age-specific norms
Rapid karyotype (FISH for X and Y)	Determine chromosomal sex quickly	XX, XY, or mosaicism (requires full karyotype)	Results in 24-48 hours; guides differential diagnosis; full karyotype takes 1-2 weeks
Pelvic/abdominal ultrasound	Identify internal structures	Uterus, gonads (location and appearance), adrenal glands, kidneys	Experienced pediatric radiologist essential; uterus confirms Müllerian development; enlarged adrenals in CAH

Clinical Pearl: Interpreting 17-OHP

17-OHP interpretation requires caution:

Premature infants: Have higher baseline 17-OHP; use gestational age-specific cutoffs
Sick/stressed infants: Stress elevates 17-OHP mildly; classic CAH causes marked elevation (usually greater than 10x normal)
Timing: Levels are higher immediately after birth; wait 36-48 hours for baseline
Mild/non-classic CAH: May have only modest elevation; steroid profile or genetic testing may be needed
Other CAH forms: 11-beta-hydroxylase and 3-beta-HSD deficiencies may have normal or only mildly elevated 17-OHP

First-Week Investigations

Once karyotype is available, targeted hormonal evaluation can proceed based on the specific differential diagnosis.

Investigation	Purpose	What to Look For	Practical Points
Full karyotype	Confirm chromosomal sex; detect mosaicism	46,XX; 46,XY; mosaicism (45,X/46,XY); structural abnormalities	Takes 1-2 weeks; essential for definitive classification; 20-30 cells analyzed to detect mosaicism
Testosterone	Assess testicular Leydig cell function	Low in gonadal dysgenesis, synthesis defects; normal/high in AIS	Measure in mini-puberty (1-3 months); need age-appropriate reference ranges
Dihydrotestosterone (DHT)	Detect 5-alpha reductase deficiency	Low DHT with normal/high testosterone; T:DHT ratio greater than 20 suggests 5-ARD	Calculate testosterone to DHT ratio; ratio greater than 20 is suggestive
Androstenedione	Assess androgen synthesis pathway	Elevated in 17-beta-HSD deficiency; high A:T ratio	Helps differentiate causes of undervirilization
Anti-Müllerian Hormone (AMH)	Assess presence and function of testicular tissue	Low/absent in gonadal dysgenesis; normal in AIS; absent in PMDS	Useful marker of Sertoli cell function; helps determine if testes are present
LH and FSH	Assess gonadotropin levels	Elevated in gonadal failure; low in hypogonadotropic hypogonadism	Measure during mini-puberty; elevated gonadotropins suggest gonadal insufficiency
Cortisol (morning)	Assess adrenal function	Low in CAH, adrenal hypoplasia	May need ACTH stimulation test if baseline is equivocal
ACTH	Assess pituitary-adrenal axis	Elevated in primary adrenal insufficiency; low in secondary	Draw with morning cortisol; elevated ACTH explains hyperpigmentation

Investigations Guided by Karyotype

If 46,XX (Virilized Female)

Investigation	Purpose	Expected Findings
17-OHP (if not already done)	Confirm/exclude 21-hydroxylase deficiency	Markedly elevated in 21-OHD; may be mildly elevated in 11-OHD
Steroid profile (11-deoxycortisol, DOC, DHEA, cortisol)	Differentiate CAH types	11-deoxycortisol elevated in 11-OHD; DHEA elevated in 3β-HSD deficiency
Plasma renin activity or aldosterone	Assess mineralocorticoid status	Elevated renin in salt-wasting; suppressed in 11-OHD
ACTH stimulation test	Unmask mild enzyme deficiencies	Exaggerated precursor response above enzyme block
Urinary steroid profile (GC-MS)	Comprehensive steroidogenesis assessment	Pattern of metabolites indicates site of enzyme block
CYP21A2 genetic testing	Confirm 21-hydroxylase deficiency	Bi-allelic pathogenic variants; guides genetic counseling
Pelvic ultrasound	Confirm normal internal female structures	Uterus and ovaries present; may see enlarged adrenals in CAH

If 46,XY (Undervirilized Male)

Investigation	Purpose	Expected Findings by Condition
Testosterone	Assess Leydig cell function	Low in gonadal dysgenesis, synthesis defects; normal/high in AIS, 5-ARD
DHT and T:DHT ratio	Screen for 5-alpha reductase deficiency	T:DHT ratio greater than 20 suggests 5-ARD; DHT low, testosterone normal/high
Androstenedione and A:T ratio	Screen for 17-beta-HSD deficiency	A:T ratio elevated in 17β-HSD3 deficiency
AMH	Assess testicular tissue presence	Low/absent in gonadal dysgenesis; normal in AIS; absent in PMDS
LH, FSH	Assess gonadotropin axis	Elevated in gonadal failure; LH elevated in AIS (androgen resistance)
hCG stimulation test	Assess testicular steroidogenic capacity	Testosterone rise indicates functional Leydig cells; poor response in dysgenesis, LCH
Precursor steroids	Identify synthesis enzyme defects	Pattern indicates site of block in steroidogenesis pathway
Pelvic MRI	Locate gonads; assess for Müllerian structures	Testis location; presence/absence of uterus
Androgen receptor gene sequencing	Confirm AIS if suspected	Pathogenic variant in AR gene (note: not found in all cases of PAIS)

If Sex Chromosome Mosaicism or Uncertain

Investigation	Purpose	Clinical Application
Extended karyotype (50+ cells)	Detect low-level mosaicism	Important in mixed gonadal dysgenesis; level of mosaicism may correlate with phenotype
Karyotype from second tissue	Detect tissue-specific mosaicism	Skin fibroblasts or gonadal tissue if blood karyotype doesn’t explain phenotype
SRY gene testing	Detect Y chromosome material	Important for gonadal malignancy risk assessment; XX males have SRY translocation
Gonadal biopsy	Definitive gonadal tissue identification	Required for diagnosis of ovotesticular DSD; assess for malignancy markers
Complete hormonal panel	Functional assessment of gonads	Testosterone, AMH, inhibin B, estradiol, gonadotropins

hCG Stimulation Test Protocol

Purpose: Assess testicular Leydig cell capacity to produce testosterone in response to stimulation (hCG mimics LH action).

Indication: 46,XY DSD with low or low-normal testosterone; assessment of gonadal function outside mini-puberty period.

Protocol (commonly used):

Draw baseline testosterone, DHT, androstenedione
Administer hCG 1,500 IU intramuscularly daily for 3 days (or single dose of 5,000 IU)
Measure testosterone, DHT, and precursors 24 hours after last dose (or 72-96 hours after single dose)

Interpretation:

Normal response: Testosterone rises to greater than 3.5 nmol/L (greater than 100 ng/dL) — functional testicular tissue present
Blunted response: Suggests gonadal dysgenesis or Leydig cell dysfunction
Elevated T:DHT ratio post-stimulation: Suggests 5-alpha reductase deficiency
Elevated precursors: Suggests specific enzyme deficiency

ACTH Stimulation Test Protocol

Purpose: Assess adrenal steroidogenesis; unmask enzyme deficiencies; confirm adrenal insufficiency.

Indication: Suspected CAH with borderline 17-OHP; suspected adrenal insufficiency; differentiation of CAH types.

Protocol:

Draw baseline cortisol, 17-OHP, and other precursors as indicated
Administer synthetic ACTH (cosyntropin) 250 mcg IV or IM (or 15 mcg/kg in neonates)
Measure cortisol and precursors at 30 and 60 minutes

Interpretation:

Normal cortisol response: Peak greater than 500 nmol/L (greater than 18 mcg/dL) excludes adrenal insufficiency
Exaggerated 17-OHP response: Confirms 21-hydroxylase deficiency
Exaggerated 11-deoxycortisol: Suggests 11-beta-hydroxylase deficiency
Pattern of precursor elevation: Indicates site of enzyme block

Imaging Studies

Imaging Modality	Indications	What to Assess	Limitations
Pelvic ultrasound	First-line imaging for all DSD	Uterus presence/size; gonad location and appearance; adrenal size; kidneys	Operator-dependent; small gonads may be missed; limited by bowel gas
Pelvic MRI	Gonads not visualized on ultrasound; surgical planning	Gonad location; internal structure; Müllerian remnants	May require sedation; expensive; not always available urgently
Genitogram (contrast study)	Define urogenital sinus anatomy; surgical planning	Urethral length; vaginal confluence level; bladder anatomy	Invasive; requires expertise; typically done later for surgical planning
Cystoscopy/vaginoscopy	Direct visualization of internal anatomy	Urogenital sinus anatomy; cervix presence; surgical planning	Requires anesthesia; typically combined with other surgical procedures

Ultrasound Findings in DSD

Uterus visualization: A visible uterus indicates Müllerian development (either no AMH production or AMH resistance). In neonates, the uterus may be prominent due to maternal estrogen effect.

Gonad appearance: Testes appear as homogeneous ovoid structures; ovaries may show small follicles; dysgenetic gonads may appear as streaks or heterogeneous tissue.

Adrenal findings: Enlarged, “cerebriform” adrenals suggest CAH (chronic ACTH stimulation causes adrenal hyperplasia).

Kidney assessment: Important as renal anomalies are associated with several DSD syndromes (WAGR, Denys-Drash).

Genetic Testing

Test	Indication	Turnaround Time	Clinical Utility
CYP21A2 sequencing	Confirm 21-hydroxylase deficiency; genetic counseling	2-4 weeks	Genotype-phenotype correlation; prenatal diagnosis in future pregnancies
Androgen receptor (AR) gene sequencing	Suspected AIS	2-4 weeks	Confirms diagnosis in CAIS; negative result doesn’t exclude PAIS (30-40% have no identifiable mutation)
SRD5A2 gene sequencing	Suspected 5-alpha reductase deficiency	2-4 weeks	Confirms diagnosis; important for prognosis (virilization at puberty expected)
DSD gene panel	Uncertain diagnosis after initial workup	4-8 weeks	Covers multiple genes; useful when phenotype doesn’t point to specific diagnosis
Whole exome/genome sequencing	Negative panel testing; syndromic features	8-12 weeks	May identify novel or rare causes; useful in complex cases
Chromosomal microarray	Suspected syndromic DSD; dysmorphic features	2-4 weeks	Detects copy number variants; identifies microdeletions/duplications

Gonadal Biopsy

Gonadal biopsy is occasionally necessary for definitive diagnosis, particularly in ovotesticular DSD and to assess malignancy risk in dysgenetic gonads.

Indication	Approach	What to Assess
Suspected ovotesticular DSD	Bilateral gonadal biopsy	Presence of both ovarian (follicles) and testicular (seminiferous tubules) tissue
Gonadal dysgenesis with Y chromosome	Biopsy or gonadectomy	Germ cell neoplasia in situ (GCNIS); gonadoblastoma; assess malignancy risk
Streak gonad suspected	Gonadectomy typically preferred over biopsy	Confirm streak tissue; exclude dysgerminoma or gonadoblastoma
Uncertain gonadal nature	Laparoscopic biopsy	Histological identification of gonadal tissue type

Investigation Summary by Clinical Scenario

Clinical Scenario	First-Line Investigations	Second-Line Investigations
Virilized infant, non-palpable gonads	17-OHP, electrolytes, glucose, karyotype, pelvic ultrasound	Steroid profile, ACTH stim test, CYP21A2 testing
Undervirilized infant, bilateral palpable gonads	Karyotype, testosterone, DHT, AMH, LH/FSH, ultrasound	hCG stimulation test, AR gene testing, steroid precursors
Ambiguous genitalia, asymmetric gonads	Karyotype (extended for mosaicism), testosterone, AMH, ultrasound	MRI, gonadal biopsy, SRY testing
Phenotypic female with inguinal masses	Karyotype, testosterone, ultrasound (expect no uterus)	AR gene testing, AMH, LH (expect elevated)
Severe hypospadias + cryptorchidism	Karyotype, testosterone, AMH, ultrasound	hCG stimulation test, DSD gene panel

7. Clinical Decision-Making

Practical algorithms and decision pathways for managing ambiguous genitalia

Clinical decision-making in disorders of sex development requires balancing urgent medical needs with the longer-term goals of accurate diagnosis and appropriate sex assignment. This section provides practical frameworks for navigating these complex decisions.

Step 1: Is This Urgent? — Triage Assessment

The first priority is identifying infants at risk of life-threatening complications, particularly salt-wasting adrenal crisis.

Clinical Scenario	Urgency Level	Immediate Action	Timeframe
Ambiguous genitalia + vomiting + lethargy + poor feeding	EMERGENT	Assume adrenal crisis; IV access; fluid resuscitation; check glucose/electrolytes; empiric hydrocortisone	Minutes
Ambiguous genitalia + hyponatremia/hyperkalemia	EMERGENT	Treat salt-wasting crisis; IV normal saline; hydrocortisone; fludrocortisone; cardiac monitoring for hyperkalemia	Minutes to hours
Ambiguous genitalia + hypoglycemia	EMERGENT	IV dextrose; investigate for cortisol deficiency; consider hypopituitarism	Minutes
Ambiguous genitalia + bilateral non-palpable gonads (well infant)	URGENT	High suspicion for CAH; check 17-OHP, electrolytes; monitor closely; daily electrolytes until CAH excluded	Hours; ongoing monitoring
Ambiguous genitalia + palpable gonads (well infant)	SEMI-URGENT	Lower risk of adrenal crisis; initiate systematic evaluation; karyotype, hormones, imaging	Days
Isolated mild hypospadias or mild clitoromegaly	ROUTINE	Outpatient evaluation appropriate; ensure newborn screening includes CAH; specialist referral	Weeks

Emergency Management of Adrenal Crisis

If salt-wasting adrenal crisis is suspected:

Immediate IV access — Draw blood for electrolytes, glucose, cortisol, 17-OHP, renin before treatment if possible (do not delay treatment for blood draw)
Fluid resuscitation — Normal saline 20 mL/kg bolus; repeat as needed; may require large volumes
Hydrocortisone — 25 mg IV bolus (neonate), then 25 mg IV every 6 hours or continuous infusion (100 mg/m²/day)
Dextrose — Add D10 to maintenance fluids; treat hypoglycemia with IV dextrose bolus
Hyperkalemia management — Calcium gluconate, insulin/glucose, sodium bicarbonate as needed; cardiac monitoring
Fludrocortisone — 0.1 mg daily once oral intake established (mineralocorticoid replacement)

Step 2: Initial Stabilization and Communication

Action	Details	Rationale
Defer sex assignment	Use neutral terms (“your baby”); avoid “boy” or “girl” until evaluation complete	Prevents need to “change” sex assignment; reduces family distress
Delay birth registration	Most jurisdictions allow delay; explain this to family	Avoids administrative complications of changing registration later
Limit examinations	Genital examination by experienced clinician only; document thoroughly; photograph with consent	Reduces trauma from repeated examinations; ensures quality documentation
Assemble multidisciplinary team	Pediatric endocrinology, urology/surgery, genetics, psychology, social work, nursing	Coordinated care improves outcomes; shared decision-making with family
Early family meeting	Within 24-48 hours; provide information; answer questions; plan next steps	Reduces anxiety; establishes therapeutic relationship; begins shared decision-making
Psychological support	Offer psychology/social work involvement from day one	Parents experience grief, confusion, guilt; early support improves coping

Step 3: Diagnostic Algorithm Based on Gonad Palpability

Pathway A: Bilateral Non-Palpable Gonads

Highest suspicion for 46,XX CAH

Check 17-OHP urgently (within 24 hours)
Daily electrolytes and glucose until CAH excluded
Pelvic ultrasound (expect uterus if 46,XX)
Rapid karyotype (FISH)
If 17-OHP elevated: start hydrocortisone, add fludrocortisone if salt-wasting
If 17-OHP normal: consider other 46,XX DSD causes or gonadal dysgenesis

Pathway B: Bilateral Palpable Gonads

Likely 46,XY DSD (lower CAH risk)

Rapid karyotype (FISH)
Testosterone, DHT, AMH, LH/FSH
Pelvic ultrasound (assess for Müllerian structures)
Calculate T:DHT ratio
If low testosterone: consider gonadal dysgenesis, synthesis defects
If normal/high testosterone: consider AIS, 5-ARD
hCG stimulation test if needed

Pathway C: Unilateral Palpable Gonad

Suggests asymmetric gonadal development

Rapid karyotype — expect mosaicism (45,X/46,XY)
Request extended karyotype (50+ cells)
Testosterone, AMH, gonadotropins
Pelvic ultrasound/MRI
Consider SRY testing
Gonadal biopsy may be needed for definitive diagnosis
Assess malignancy risk — high in dysgenetic gonads with Y

Pathway D: Phenotypic Female + Inguinal Masses

Suspect androgen insensitivity syndrome

Rapid karyotype — expect 46,XY
Testosterone (expect normal male or elevated)
LH (expect elevated due to androgen resistance)
Pelvic ultrasound (expect absent uterus)
AMH (expect normal — testes present)
AR gene sequencing
Counsel regarding diagnosis, gonad management

Step 4: Interpreting Key Investigation Results

Finding	Interpretation	Next Steps
17-OHP markedly elevated (greater than 300 nmol/L)	21-hydroxylase deficiency confirmed	Start hydrocortisone; assess for salt-wasting (electrolytes, renin); fludrocortisone if needed; CYP21A2 genetic testing
46,XX + uterus present + normal 17-OHP	Non-CAH 46,XX DSD (aromatase deficiency, maternal exposure, other enzyme defect)	Detailed steroid profile; maternal history review; consider genetic testing for rare causes
46,XY + low testosterone + low AMH	Gonadal dysgenesis or regression	Imaging to locate gonads; assess malignancy risk; hCG stimulation test; consider gonadectomy for dysgenetic tissue
46,XY + normal/high testosterone + normal AMH + T:DHT greater than 20	5-alpha reductase deficiency	SRD5A2 genetic testing; counsel regarding virilization at puberty; discuss sex assignment considerations
46,XY + high testosterone + high LH + female phenotype	Androgen insensitivity syndrome	AR gene sequencing; pelvic imaging (confirm absent uterus, locate testes); discuss gonad management timing
45,X/46,XY mosaicism	Mixed gonadal dysgenesis	Assess both gonads (one streak, one dysgenetic testis typical); high malignancy risk; individualized gonad management
Testosterone does not rise with hCG stimulation	Leydig cell dysfunction or absence; gonadal dysgenesis	Gonadal imaging; assess for gonadal tissue; consider anorchia or severe dysgenesis

Step 5: Sex Assignment Considerations

Sex assignment is one of the most consequential decisions in DSD management. It should be made by an experienced multidisciplinary team in partnership with the family, based on the best available evidence and individualized to each case.

Factors Influencing Sex Assignment

Medical factors:

Specific diagnosis and etiology
Genital anatomy and surgical options
Potential for fertility (ovarian tissue, uterus, sperm production)
Endogenous hormone production and requirements
Expected pubertal development

Psychosocial factors:

Predicted gender identity (based on diagnosis, prenatal androgen exposure)
Family preferences and cultural context
Available support systems
Long-term psychological outcomes data
Patient autonomy considerations

Condition	Typical Sex Assignment	Key Considerations
46,XX CAH	Female (in vast majority)	Ovaries and uterus present; fertility possible; female gender identity in most; lifelong glucocorticoid replacement needed
Complete AIS (46,XY)	Female	Female external genitalia; female gender identity; testes produce estrogen at puberty (if retained); no uterus so no fertility; gonadectomy timing debated
5-Alpha Reductase Deficiency	Variable — often male if diagnosed early	Significant virilization at puberty; high rate of male gender identity; fertility possible as male; if raised female, gender change common at puberty
Partial AIS	Variable — individualized	Wide phenotypic spectrum; gender identity difficult to predict; outcomes data mixed; shared decision-making essential
Mixed Gonadal Dysgenesis	Variable — individualized	Depends on degree of masculinization, gonadal function, anatomy; malignancy risk requires gonad management planning
Complete Gonadal Dysgenesis (Swyer)	Female	Female phenotype; uterus present; fertility possible with egg donation; gonadectomy needed due to malignancy risk
Ovotesticular DSD	Variable — individualized	Depends on anatomy and gonadal function; some fertility potential; tissue-preserving surgery when possible

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Key Considerations
Family is pressuring for immediate sex assignment	Acknowledge distress; explain importance of accurate diagnosis; provide timeline	Sex assignment within days to weeks is appropriate; rushing may lead to incorrect assignment; psychological support essential
Extended family or community is asking questions	Help family develop a simple script; respect their privacy preferences	“The baby needs some tests before we can confirm the sex” is often sufficient; family decides what to share
17-OHP is mildly elevated but not clearly diagnostic	Repeat 17-OHP; consider ACTH stimulation test; continue monitoring electrolytes	Prematurity, stress, and cross-reactivity can elevate 17-OHP; use gestational age norms; genetic testing may be needed
Karyotype is 46,XY but infant appears female	Consider CAIS, complete gonadal dysgenesis; check testosterone, AMH, ultrasound for uterus	High testosterone with no uterus suggests CAIS; low testosterone with uterus suggests gonadal dysgenesis
Parents want to “wait and see” before any sex assignment	This is acceptable if safe; ensure follow-up plan; provide psychological support	Prolonged delay can be challenging for family; support parents through uncertainty; avoid indefinite deferral
Diagnosis remains uncertain despite full evaluation	Extended genetic testing (DSD panel, exome); gonadal biopsy if indicated; experienced DSD center referral	Some cases remain undiagnosed; sex assignment may proceed based on best available information with appropriate counseling
Family requests early genital surgery	Discuss current recommendations; explain risks and benefits; respect family autonomy within ethical bounds	Trend toward deferring irreversible surgery; emergency procedures only if medically necessary; individualized shared decision-making
Y chromosome material found in phenotypic female	Assess gonadal malignancy risk; imaging to locate gonads; plan for monitoring or gonadectomy	Risk varies by condition (high in gonadal dysgenesis, lower in CAIS); timing of gonadectomy depends on diagnosis

Step 6: Long-Term Management Planning

Management Area	Key Considerations	Specialist Involvement
Hormone replacement	Glucocorticoids and mineralocorticoids in CAH; sex hormone replacement at puberty if needed	Pediatric endocrinology; transition to adult endocrinology
Surgical considerations	Timing and type of genital surgery (if any); gonadectomy for malignancy risk; fertility preservation	Pediatric urology/surgery; reproductive medicine
Psychological support	Ongoing support for patient and family; age-appropriate disclosure; peer support connections	Psychology/psychiatry with DSD expertise
Fertility counseling	Realistic assessment of fertility potential; options such as egg/sperm donation, surrogacy, adoption	Reproductive endocrinology; genetic counseling
Gonadal monitoring	Tumor markers, imaging, or planned gonadectomy depending on malignancy risk	Endocrinology; oncology if needed
Transition to adult care	Structured transition program; adult DSD clinic if available; ensure continuity	Multidisciplinary transition team

Principles of Decision-Making in DSD

Safety first: Identify and treat life-threatening conditions immediately
Accurate diagnosis: Invest time in establishing the correct diagnosis before making irreversible decisions
Multidisciplinary care: No single specialist has all the expertise needed; team-based care is essential
Family-centered: Parents are partners in decision-making; support them through the process
Patient-centered: Consider the future person’s autonomy and well-being
Evidence-based: Use the best available evidence while acknowledging uncertainty
Individualized: Each case is unique; avoid one-size-fits-all approaches
Long-term perspective: Decisions made now will affect the patient for life

8. Clinical Pearls and Pitfalls

Practical wisdom — key insights and common mistakes to avoid

Must-Know Clinical Pearls

The palpable gonad rule: A gonad palpable in the labioscrotal fold or inguinal canal is almost always a testis (or contains testicular tissue). Ovaries do not descend. Bilateral non-palpable gonads in an infant with ambiguous genitalia suggests 46,XX DSD (likely CAH) until proven otherwise.

The 7-14 day danger zone: Salt-wasting adrenal crisis in CAH typically presents between days 7-14 of life. The first week may be deceptively calm due to residual maternal steroids. Maintain vigilance and daily electrolyte monitoring during this critical window.

Male newborns with CAH can die undiagnosed: 46,XY males with salt-wasting CAH have normal-appearing genitalia. Without newborn screening, they may present only with adrenal crisis and die of presumed “sepsis.” Always consider CAH in a critically ill male neonate with hyponatremia and hyperkalemia.

The presence of a uterus is informative: A uterus indicates that anti-Müllerian hormone was absent or non-functional during development. This excludes functioning testicular Sertoli cells and helps narrow the differential significantly.

Hyperpigmentation is a clinical sign of elevated ACTH: Dark areolae, hyperpigmented genitalia, and pigmented skin creases in a newborn with ambiguous genitalia strongly suggest congenital adrenal hyperplasia with cortisol deficiency driving ACTH elevation.

The mini-puberty window: The first 3-6 months of life offer a unique diagnostic window when the hypothalamic-pituitary-gonadal axis is active. Testosterone, gonadotropins, and AMH are most informative during this period. After 6 months, baseline levels decline and stimulation tests may be needed.

AMH is a marker of testicular tissue: Anti-Müllerian hormone is produced by Sertoli cells. A measurable AMH level indicates the presence of testicular tissue, even if testes are not palpable or visible on imaging. Low or absent AMH suggests gonadal dysgenesis or anorchia.

Some conditions “reveal themselves” at puberty: 5-alpha reductase deficiency and 17-beta-hydroxysteroid dehydrogenase deficiency may present with female or ambiguous genitalia at birth but undergo dramatic virilization at puberty. Early diagnosis allows informed decision-making about sex assignment.

Critical Pitfalls to Avoid

Assuming bilateral non-palpable gonads means bilateral cryptorchidism: In an infant with ambiguous genitalia and bilateral non-palpable gonads, the most likely diagnosis is 46,XX CAH — not bilateral undescended testes. This distinction is critical because CAH carries risk of life-threatening salt-wasting crisis.

Discharging before CAH is excluded: Never discharge an infant with ambiguous genitalia and non-palpable gonads until CAH has been excluded or appropriate monitoring and follow-up are arranged. The salt-wasting crisis typically occurs after discharge from the birth hospital.

Measuring 17-OHP too early: 17-hydroxyprogesterone is physiologically elevated in the first 24-36 hours of life and can be elevated by stress or prematurity. A sample drawn too early may be falsely positive or may not yet show the diagnostic elevation of CAH. Optimal timing is after 36-48 hours.

Rushing sex assignment: Pressure from family or administrative requirements should not drive premature sex assignment. Taking a few days to weeks to establish an accurate diagnosis is far better than making an incorrect assignment that may need to be changed.

Using gendered language before sex assignment: Referring to the baby as “he” or “she” before sex assignment creates confusion and distress if the assignment differs from initial assumptions. Use neutral terms such as “your baby” or the infant’s surname until assignment is made.

Repeated genital examinations by multiple providers: Each examination causes distress to the family and potentially to the infant. Genital examination should be performed by an experienced clinician, documented thoroughly (including photographs with consent), and shared with the team rather than repeated.

Forgetting the malignancy risk: Dysgenetic gonads containing Y chromosome material carry significant malignancy risk (gonadoblastoma, dysgerminoma). This risk must be assessed and a plan made for monitoring or gonadectomy. The risk varies by condition — do not assume all Y-containing gonads have the same risk.

Assuming normal testosterone means normal androgen function: In androgen insensitivity syndrome, testosterone levels are normal or elevated, but tissues cannot respond. A normal testosterone level does not exclude disorders of androgen action.

Missing the family history: Many DSD conditions are inherited. Unexplained neonatal deaths, “infertile aunts,” relatives with genital surgery, or consanguinity may be critical clues. Families may not volunteer this information unless specifically asked.

Neglecting psychological support: Families experience significant distress when their baby has ambiguous genitalia. Early psychological support improves coping and long-term outcomes for both family and child. Do not wait until there is a “problem” to involve psychology.

Key Takeaways

Ambiguous genitalia is a medical and psychosocial emergency requiring urgent multidisciplinary evaluation and family support.
The most common cause of ambiguous genitalia is 21-hydroxylase deficiency (CAH), which can be life-threatening due to salt-wasting adrenal crisis.
Bilateral non-palpable gonads in an infant with ambiguous genitalia means “think CAH first” — monitor electrolytes closely and do not discharge until CAH is excluded.
A palpable gonad is almost always a testis — this simple examination finding dramatically narrows the differential diagnosis.
Karyotype determines the diagnostic category (46,XX DSD, 46,XY DSD, or sex chromosome DSD) and guides the subsequent workup.
The presence or absence of a uterus indicates whether Müllerian structures developed (no functional AMH) or regressed (functional Sertoli cells produced AMH).
Sex assignment should be made by a multidisciplinary team in partnership with the family, based on diagnosis, anatomy, predicted gender identity, and fertility potential.
Use neutral language and defer birth registration until sex assignment is made — this prevents the need to “change” the assigned sex.
Dysgenetic gonads with Y chromosome material carry malignancy risk — assess risk and plan for monitoring or gonadectomy based on the specific diagnosis.
Long-term follow-up is essential — hormone replacement, surgical considerations, psychological support, and transition to adult care must all be planned.

Quick Reference Algorithm

Systematic Approach to the Newborn with Ambiguous Genitalia:

Stabilize and screen for emergencies: Check electrolytes, glucose, 17-OHP; assess for signs of adrenal crisis; initiate monitoring.
Communicate with family: Use neutral language; explain the need for evaluation; provide psychological support; defer birth registration.
Perform systematic examination: Document genital findings objectively; assess for palpable gonads; look for associated anomalies; photograph with consent.
Determine karyotype: Rapid FISH for X and Y (24-48 hours) followed by full karyotype; this categorizes the DSD.
Pelvic imaging: Ultrasound to identify uterus, locate gonads, assess adrenals and kidneys.
Targeted hormonal workup: Based on karyotype — 17-OHP and steroid profile for 46,XX; testosterone, DHT, AMH for 46,XY.
Assemble multidisciplinary team: Pediatric endocrinology, urology/surgery, genetics, psychology, social work.
Establish diagnosis: Integrate clinical, biochemical, imaging, and genetic findings.
Sex assignment discussion: Multidisciplinary team with family; consider diagnosis, anatomy, predicted gender identity, fertility.
Plan long-term management: Hormone replacement, surgical timing, psychological support, gonadal monitoring, transition planning.

Emergency Reference Card

Emergency	Recognition	Immediate Management
Salt-wasting adrenal crisis	Vomiting, lethargy, poor feeding, dehydration; hyponatremia (less than 130), hyperkalemia (greater than 6); typically day 7-14	IV NS 20 mL/kg bolus; hydrocortisone 25 mg IV; dextrose for hypoglycemia; treat hyperkalemia; fludrocortisone when stable
Hypoglycemia	Glucose less than 2.6 mmol/L; jitteriness, lethargy, seizures	IV dextrose 2 mL/kg of D10W; maintain glucose infusion; investigate for cortisol deficiency
Hyperkalemia with cardiac effects	Peaked T waves, widened QRS, bradycardia; K greater than 7	Calcium gluconate 100 mg/kg IV; insulin/glucose; sodium bicarbonate; urgent hydrocortisone if CAH suspected

Key Diagnostic Patterns at a Glance

Pattern	Most Likely Diagnosis	Confirmatory Test
46,XX + virilization + non-palpable gonads + elevated 17-OHP + uterus present	21-Hydroxylase deficiency (CAH)	CYP21A2 genetic testing
46,XY + female phenotype + palpable inguinal gonads + no uterus + high testosterone	Complete androgen insensitivity syndrome	AR gene sequencing
46,XY + ambiguous genitalia + T:DHT ratio greater than 20 + consanguinity	5-Alpha reductase deficiency	SRD5A2 genetic testing
45,X/46,XY + asymmetric gonads + ambiguous genitalia	Mixed gonadal dysgenesis	Extended karyotype; gonadal biopsy
46,XY + female phenotype + uterus present + low testosterone + low AMH	Complete gonadal dysgenesis (Swyer syndrome)	Gonadal imaging; genetic testing for SRY and other genes
46,XX + virilization + maternal virilization during pregnancy + normal 17-OHP	Aromatase deficiency or maternal androgen source	Estrogen levels; CYP19A1 genetic testing; maternal evaluation